Phase 3
Completed N=240
A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Source: ClinicalTrials.gov NCT01940497 ↗Enrolled (actual)
240
Serious AEs
7.5%
Results posted
Jul 2017
Primary outcomePrimary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 98.9; 100.0; 89.1; 95.2 Percentage of Participants
◆ Published Evidence
Emerging
12citations · ~2 / year
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
Summary
This non-randomized, multicenter, open-label study will assess the safety and efficacy of subcutaneously administered trastuzumab in participants with early and locally advanced HER2-positive breast cancer in two sequential cohorts. First 120 participants will be treated with subcutaneous (SC) trastuzumab 600 milligrams (mg) vial (Cohort A) and the subsequent 120 participants will be treated with SC trastuzumab prefilled single use injection device (SID) (Cohort B). Participants from each cohort will receive neoadjuvant or adjuvant chemotherapy consisting of doxorubicin every 3 weeks (q3w) (1 cycle) for 4 cycles followed by paclitaxel weekly or docetaxel every 3 weeks (q3w) in combination with SC trastuzumab (600 mg) q3w for 4 cycles and a further 14 cycles of SC trastuzumab (600 mg) q3w alone. All participants will be followed up for 24 months after the last participant has received the last dose of study treatment, or earlier in case of withdrawal from the study, loss to follow-up or death.
Linked Publications
-
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) |
98.9; 100.0; 89.1; 95.2 | — |
| SECONDARY Actual Dose of Trastuzumab Administered |
599.7; 600.00; 593.3; 595.9 | — |
| SECONDARY Duration of Treatment With Trastuzumab |
346; 352.2; 340.1; 351.9 | — |
| SECONDARY Percentage of Participants Who Received Concomitant Medications |
100; 100 | — |
| SECONDARY Percentage of Participants With Pathological Complete Response (pCR) (Neoadjuvant Groups Only) Using Mammography |
40.9; 15.8 | — |
| SECONDARY Percentage of Participants With Event (Local, Regional or Distant Recurrence, Contralateral Breast Cancer or Death) Using Mammography |
18.5; 33.3; 6.6; 11.1 | — |
| SECONDARY Disease-Free Survival (DFS) Using Mammography |
NA; NA; NA; NA | — |
| SECONDARY Percentage of Participants Who Died |
5.2; 4.5; 0.0; 5.26 | — |
| SECONDARY Overall Survival (OS) |
NA; NA; NA; NA | — |
| SECONDARY Percentage of Participants by Response to Patient Satisfaction Questionnaire (PSQ) |
0.0; 0.0; 0.0; 6.7; 40; 53.3 | — |
| SECONDARY Percentage of Health Care Professionals (HCPs) by Response to Health Care Professional Questionnaire (HCPQ) |
17.3; 16.0; 69.2; 76.0; 11.5; 8.0 | — |
Eligibility Criteria
Inclusion Criteria
- Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast. Stage of disease: T1-4 (T describes size of tumour from 1 to 4), N0-3 (N describes nearby lymph nodes), M0 (M describes distant metastasis)
- HER2-positive disease immunohistochemistry (IHC) 3+ or in situ hybridization (ISH) positive
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Left ventricular ejection fraction (LVEF) of greater than or equal to (>=) 55 percent (%) measured by echocardiography (ECHO) or multiple gated acquisition (MUGA) scan prior to first dose of trastuzumab SC
- Intact skin at site of SC injection on the thigh
Exclusion Criteria
- History of other malignancy, except for participants with curatively treated carcinoma in situ of the cervix or basal cell carcinoma and participants with other curatively treated malignancies, other than breast cancer, who have been disease-free for at least 5 years
- Severe dyspnea at rest or requiring supplementary oxygen therapy
- Concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness
- Serious cardiac illness or medical conditions that would preclude the use of trastuzumab, specifically: history of documented congestive heart failure (CHF), high-risk uncontrolled arrhythmias, angina pectoris requiring medication, clinically significant valvular disease, evidence of transmural infarction on electrocardiogram (ECG), diagnosed poorly controlled hypertension
- Known infection with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus (HCV)
- Pregnant or lactating women
- Concurrent enrolment in another clinical trial using an investigational anti-cancer treatment, including hormonal therapy, bisphosphonate therapy and immunotherapy, within 28 days prior to the first dose of study treatment
- Known hypersensitivity to trastuzumab, murine proteins, to any of the excipients of Herceptin including hyaluronidase, or the adhesive of the SC device (for Cohort B), or a history of severe allergic or immunological reactions, for example, difficulty to control asthma
- Inadequate bone marrow, hepatic or renal function
- Hormonal treatment concomitant with chemotherapy (allowed in adjuvant phase with adjuvant trastuzumab SC)
- Pre-existing motor or sensory neuropathy of Grade greater than (>) 1
- Synchronous bilateral invasive breast cancer
Data sourced from ClinicalTrials.gov (NCT01940497) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.